US-based Exact Sciences Corporation intends to raise $245m in gross proceeds through a public offering of its common stock shares.

The offering includes seven million shares priced at $35 a share, while underwriters have an option to purchase up to an additional 1.05 million shares.

The proceeds will be used to mainly expand the commercialisation activities of Cologuard, a non-invasive, colon cancer at-home test. Part of the proceeds will also be used for product development and for general corporate and working capital purposes.

"Israeli-based Tisbury Pharmaceuticals has announced its completion of the first round of venture financing to raise $32m from OrbiMed Advisors, Clarus Healthcap, and Pontifax."

US-based pharmaceutical company Egalet Corporation and Ascend Therapeutics US have signed a two-year co-promotion agreement for SPRIX (ketorolac tromethamine), a nasal spray used for management of moderate-to-moderately severe pain.

Ascend Therapeutics’ team will help co-promote the product as part of the agreement, starting from this year's third quarter.

Israeli-based Tisbury Pharmaceuticals has announced its completion of the first round of venture financing to raise $32m from OrbiMed Advisors, Clarus Healthcap, and Pontifax.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The proceeds are intended to be used to conduct human trials and develop other glaucoma drugs.